Commercial Novo Nordisk to launch Ozempic for type 2 diabetes in US Pharmaceutical TechnologyNovo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.Metabolic & GLP-1Read full story pharminent May 4, 2026 (Last updated: May 4, 2026) Pharmaceutical Technology Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer, Arvinas join SERD club with Veppanu approvalNext: UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026
